Self-Assessment Method for Statin side-effects Or Nocebo 2

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524955-30-01

Enrollment

160

Registered

2026-06-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular diseases

Brief summary

Proportion of patients taking rosuvastatin 20mg daily at 6 months

Detailed description

• To compare the proportion of patients who continue any statin treatment six months after participating in a 36-week N-of-1 trial versus standard of care (statin titration) in patients with previously reported statin intolerance.

Interventions

DRUGROSUVASTATIN

DRUGThe placebo product does not contain active substance and is otherwise identical to the IMP.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of patients taking rosuvastatin 20mg daily at 6 months	—

Secondary

Measure	Time frame
• To compare the proportion of patients who continue any statin treatment six months after participating in a 36-week N-of-1 trial versus standard of care (statin titration) in patients with previously reported statin intolerance.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 29, 2026